|
Market Closed -
NYSE
16:00:02 2026-10-15 EDT
|
5-day change | 1st Jan Change | ||
| 166.68 USD | +2.87% |
|
+1.19% | +81.28% |
| 12:32pm | European Stocks Close Higher in Thursday Trading on Strong Earnings; Investors Parse Hot US Inflation Report | MT |
| 12:29pm | RBC Reaffirms AstraZeneca's Outperform Rating Ahead of Q3 Results | MT |
Company Valuation: AstraZeneca PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 182,034 | 209,442 | 209,268 | 203,171 | 287,813 | 250,873 | - | - |
| Change | - | 15.06% | -0.08% | -2.91% | 41.66% | -12.83% | - | - |
| Enterprise Value (EV) 1 | 206,417 | 232,365 | 231,778 | 227,741 | 311,187 | 270,813 | 263,178 | 255,039 |
| Change | - | 12.57% | -0.25% | -1.74% | 36.64% | -12.97% | -2.82% | -3.09% |
| P/E | 1,469x | 64.1x | 35.4x | 29.1x | 28.4x | 21.1x | 18.2x | 16.2x |
| PBR | 4.24x | 5.65x | 5.39x | 5.02x | 5.96x | 4.64x | 4.02x | 3.46x |
| PEG | - | 0x | 0.4x | 1.6x | 0.6x | 1.2x | 1.1x | 1.4x |
| Capitalization / Revenue | 4.87x | 4.72x | 4.57x | 3.76x | 4.9x | 3.96x | 3.73x | 3.52x |
| EV / Revenue | 5.52x | 5.24x | 5.06x | 4.21x | 5.3x | 4.27x | 3.91x | 3.58x |
| EV / EBITDA | 27.2x | 25.2x | 17.1x | 13.6x | 16x | 12.3x | 10.8x | 9.54x |
| EV / EBIT | 20.8x | 17.4x | 15.9x | 13.5x | 16.8x | 12.9x | 11.3x | 9.98x |
| EV / FCF | 42.4x | 26.7x | 25.8x | 22.9x | 26.5x | 27.9x | 20.8x | 17.6x |
| FCF Yield | 2.36% | 3.75% | 3.88% | 4.36% | 3.78% | 3.59% | 4.81% | 5.67% |
| Dividend per Share 2 | 2.87 | 2.9 | 2.9 | 3.1 | 3.2 | 3.342 | 3.547 | 3.655 |
| Rate of return | 2.44% | 2.15% | 2.15% | 2.37% | 1.72% | 2.07% | 2.19% | 2.26% |
| EPS 2 | 0.08 | 2.11 | 3.81 | 4.5 | 6.54 | 7.648 | 8.906 | 9.969 |
| Distribution rate | 3,588% | 137% | 76.1% | 68.9% | 48.9% | 43.7% | 39.8% | 36.7% |
| Net sales 1 | 37,417 | 44,351 | 45,811 | 54,073 | 58,739 | 63,372 | 67,235 | 71,323 |
| EBITDA 1 | 7,586 | 9,237 | 13,580 | 16,691 | 19,476 | 22,081 | 24,275 | 26,729 |
| EBIT 1 | 9,928 | 13,350 | 14,534 | 16,928 | 18,478 | 21,047 | 23,243 | 25,561 |
| Net income 1 | 112 | 3,288 | 5,961 | 7,035 | 10,225 | 11,805 | 13,729 | 15,339 |
| Net Debt 1 | 24,383 | 22,923 | 22,510 | 24,570 | 23,374 | 19,941 | 12,305 | 4,166 |
| Reference price 2 | 117.51 | 135.16 | 135.02 | 131.05 | 185.60 | 161.75 | 161.75 | 161.75 |
| Nbr of stocks (in thousands) | 1,549,159 | 1,549,528 | 1,549,926 | 1,550,317 | 1,550,726 | 1,551,024 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/8/24 | 2/6/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 34.58x | 12.46x | 26.12x | 0.57% | 1,077B | |
| 37.53x | 6.26x | 17.55x | 2.1% | 612B | |
| 36.12x | 8.31x | 17.13x | 2.45% | 501B | |
| 113.84x | 6x | 25.7x | 2.32% | 364B | |
| 20.01x | 4.88x | 12.13x | 2.7% | 353B | |
| 20.46x | 5.37x | 13.21x | 2.96% | 278B | |
| 21.15x | 4.27x | 12.26x | 2.07% | 251B | |
| 27.06x | 6.97x | 12.48x | 2.37% | 230B | |
| -44.86x | 6.85x | 26.64x | 2.14% | 190B | |
| Average | 29.54x | 6.82x | 18.14x | 2.19% | 428.5B | |
| Weighted average by Cap. | 35.12x | 7.99x | 19.65x | 1.87% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
- Valuation AstraZeneca PLC
Select your edition
All financial news and data tailored to specific country editions
